China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.7
38.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
Cash & Cash Equivalents
China Resources Boya Bio pharmaceutical Group Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Cash & Cash Equivalents
ÂĄ3.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
41%
|
CAGR 10-Years
26%
|
||
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
ÂĄ15B
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Cash & Cash Equivalents
ÂĄ2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash & Cash Equivalents
ÂĄ3.8B
|
CAGR 3-Years
75%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash & Cash Equivalents
ÂĄ1.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash & Cash Equivalents
ÂĄ5.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
20%
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.2B
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Cash & Cash Equivalents amounts to 3.2B CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
26%
Over the last year, the Cash & Cash Equivalents growth was 21%. The average annual Cash & Cash Equivalents growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 44% over the past three years , 41% over the past five years , and 26% over the past ten years .